European Heart Journal Supplements · 2004 · 88 citations · 29 references
MedicineCardiologyPharmacoeconomicsCardiovascular PharmacotherapyClinical CardiologyPreventive CardiologyCardiac MedicationsCardiac PharmacotherapyCardiovascular DiseaseHeart FailureHeart Failure PharmacotherapyHypertension ManagementAldosterone AntagonismAldosterone AntagonistsChronic Heart Failure ManagementCongestive Heart Failure ManagementEconomic Burden Of DiseaseEconomic Burden Of IllnessHealthcare ResourcesHeart Failure Epidemiology
Chronic heart failure is a major cause of morbidity and mortality in the general population. Both, the increasing age of the population and success in the treatment of patients with acute myocardial infarction rise the prevalence and thus the economic expenditures of chronic heart failure. This holds true despite recent improvement in survival of patients with congestive heart failure due to treatment with ACE inhibitors, b-adrenoceptor blockers and aldosterone antagonists. Chronic heart failure consumes 1-2% of the total healthcare resources in the industrialised countries with increasing tendency in future. The most effective approach for preventing heart failure is an improvement in diagnosis and consequent treatment of arterial hypertension. Evidence based treatment of congestive heart failure is both effective in lowering morbidity and mortality as well as cost-effective from an economic point of view.
29
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet · 1999 · 4.9K citations
Medicine, Cardiology, Pharmacology +10